Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and wcophenolate mofetil

Transplantation

Volumn 72, Issue 10, 2001, Pages 1675-1679

  Washburn, Kenneth ^a   Speeg, K V ^a   Esterl, Robert ^a   Cigarroa, Francisco ^a   Pollack, Marilyn ^a   Tourtellot, Cyndi ^a   Maxwell, Pam ^a   Halff, Glenn ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; COTRIMOXAZOLE; FLUCONAZOLE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT REJECTION; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035960584     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200111270-00018     Document Type: Article

References (24)

1. Corticosteroids withdrawal 14 days after liver transplantation with mycophenolate mofetil
2. A pilot study on the safety and effectiveness of immunosuppression without corticosteroids after liver transplantation
3. Steroid withdrawal from long-term immunosuppression in liver allograft recipients
4. Withdrawal of immunosuppression in liver allograft recipients
5. Early cyclosporine monotherapy in liver transplantation: A 5-year follow-up of a prospective, randomized trial
6. Long-term immunosuppression without corticosteroids after orthotopic liver transplantation: A positive therapeutic aim
7. Early steroid withdrawal after liver transplantation
8. Steroid withdrawal is safe and beneficial in stable cyclosporine-treated liver transplant patients
9. Maintenance immunosuppression using cyclosporine monotherapy in adult orthotopic liver transplant recipients
10. Corticosteroid withdrawal after liver transplantation
11. The effect ofimmunosuppression on growth and development
12. Factors affecting growth after pediatric liver transplantation
13. Growth in children after liver transplantation on cyclosporine alone or in combination with low-dose azathioprine
14. Linear growth after pediatric liver transplantation
15. Effect of immunosuppression and antiviral agents on hepatitis B, in vitro
16. Long-term outcome of hepatitis C infection in liver transplantation
17. The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients
18. Experience with daclizumab in liver transplantation
19. Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation
20. Evolution of cardiovascular risk after liver transplantation: A comparison of cyclosporine A and tacrolimus (FK505)
21. Tacrolimus (FK506) is superior to cyclosporine in liver transplantation
22. Bone disease after liver transplantation
23. Glucocorticoid-induced osteoporosis: Pathogenesis and management
24. Predictors of patient and graft survival following liver transplantation for hepatitis C